Back to List/Filter


M16-109

NCT03222609

A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis
Alfred Health (Haematology)
The Alfred, Commercial Road, Melbourne VIC, Australia
Recruiting
Primary Contact : Nola Kennedy, N.Kennedy@alfred.org.au , 03 9076 2217
Fiona Stanley Hospital (Haematology)
11 Robin Warren Dr, Murdoch WA 6150, Australia
Recruiting
Primary Contact : Wendy Angelatos, wendy.angelatos@health.wa.gov.au , 08 6152 6540
Peter MacCallum, Parkville Cancer Clinical Trials Unit (PCCTU) (Haematology)
Peter MacCallum Cancer Centre, Grattan Street, Melbourne VIC, Australia
Closed
Primary Contact : Enquiry Line Coordinator, clinicaltrials.enquiries@petermac.org , +613 8559 7456
St Vincents Hospital, Sydney (Haematology)
Darlinghurst, Sydney, NSW
Recruiting
Primary Contact : Louise Christopherson, louise.christophersen@svha.org.au , 02 9355 5702

2017-001398-17M16-109

Interventional

Treatment - Drugs

Phase 2

18

100

04/06/2020

N/A

Open

By Specialist and/or Surgeon Referral

Any or not stated

No

No

No
Haematology
Myeloproliferative Disorders
Myelofibrosis
N/A

20060540